The current financial score of Co-Diagnostics Inc is 5.99. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 166.13K, representing a year-over-year increase of 1.98%, while its net profit experienced a year-over-year increase of 18.71%.
The current valuation score of Co-Diagnostics Inc is 1.00. Its current P/E ratio is -0.00, which is 0.00% below the recent high of -0.00 and -795811.11% above the recent low of -7.16.
The current earnings forecast score of Co-Diagnostics Inc is 8.00. The average price target is 4.00, with a high of 4.00 and a low of 4.00.
The current price momentum score of Co-Diagnostics Inc is 4.99. Currently, the stock price is trading between the resistance level at 1.19 and the support level at 0.81, making it suitable for range-bound swing trading.
The current institutional shareholding score of Co-Diagnostics Inc is 3.00. The latest institutional shareholding proportion is 6.89%, representing a quarter-over-quarter decrease of 48.69%. The largest institutional shareholder is James Simons, holding a total of 12.50K shares, representing 0.00% of shares outstanding, with 79.46% decrease in holdings.
The current risk assessment score of Co-Diagnostics Inc is 1.71. The company's beta value is 2.91. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.